News Releases
May 17, 2022
Biodesix to Present at the H.C. Wainwright Global Investment Conference
May 12, 2022
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference
May 11, 2022
Biodesix Announces First Quarter 2022 Results and Highlights
Apr 27, 2022
Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
Apr 11, 2022
Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan
Mar 29, 2022
Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer
Mar 14, 2022
Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights
Mar 07, 2022
Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital
Mar 03, 2022
Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of Lung Cancer Meeting
Mar 01, 2022
Biodesix to Present at Cowen’s 42nd Annual Healthcare Conference
Displaying 1 - 10 of 16